{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "8463657",
  "DateCompleted": {
    "Year": "1993",
    "Month": "05",
    "Day": "06"
  },
  "DateRevised": {
    "Year": "2016",
    "Month": "11",
    "Day": "23"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0891-5520",
      "JournalIssue": {
        "Volume": "7",
        "Issue": "1",
        "PubDate": {
          "Year": "1993",
          "Month": "Mar"
        }
      },
      "Title": "Infectious disease clinics of North America",
      "ISOAbbreviation": "Infect Dis Clin North Am"
    },
    "ArticleTitle": "Ceftriaxone and outpatient treatment of infective endocarditis.",
    "Pagination": {
      "StartPage": "97",
      "EndPage": "115",
      "MedlinePgn": "97-115"
    },
    "Abstract": {
      "AbstractText": [
        "There are a total of 8000 cases of infective endocarditis yearly in the United States. Central nervous system metastatic infections are not uncommon in infective endocarditis. Because ceftriaxone is highly bound to serum proteins, there is concern that the drug is highly bound to serum proteins, there is concern that the drug might not penetrate well in the core of an infected vegetation. To date, there are two published studies on the treatment of nonenterococcal streptococcal endocarditis by ceftriaxone in humans. Ceftriaxone appears to be an attractive alternative antibiotic therapy to conventional regimens in the treatment of streptococcal endocarditis."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Hospital Preventive Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland."
          }
        ],
        "LastName": "Francioli",
        "ForeName": "P B",
        "Initials": "PB"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Infect Dis Clin North Am",
    "NlmUniqueID": "8804508",
    "ISSNLinking": "0891-5520"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "75J73V1629",
      "NameOfSubstance": "Ceftriaxone"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Ambulatory Care"
    },
    {
      "QualifierName": [
        "etiology"
      ],
      "DescriptorName": "Aneurysm, Infected"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Ceftriaxone"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Costs and Cost Analysis"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Drug Therapy, Combination"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Echocardiography"
    },
    {
      "QualifierName": [
        "etiology"
      ],
      "DescriptorName": "Embolism"
    },
    {
      "QualifierName": [
        "complications",
        "diagnostic imaging",
        "drug therapy"
      ],
      "DescriptorName": "Endocarditis, Bacterial"
    },
    {
      "QualifierName": [
        "etiology"
      ],
      "DescriptorName": "Heart Failure"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy"
      ],
      "DescriptorName": "Staphylococcal Infections"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy"
      ],
      "DescriptorName": "Streptococcal Infections"
    }
  ],
  "NumberOfReferences": "67"
}